الفهرس Only 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
The discovery and development of muscle relaxants has a long history. Griffith and Johnson (1942), introduced curare into anaesthetic practice to provide muscle relaxation.. Gallamine triethiodide, was first used clinically by Hunguenard and Bone (1948) in France.. A year later, decamethonium; an intermediate acting depolarizing relaxant, was described by Orgone et at (1949). Succinylcholine was next introduced by Theslet (1951) and Folds (1952)(3).
Alcuronium was introduced by Hugin and Kissliny (1961) Pancuronium was introduced by Baird and Reid (1968) . Four years later fazadinium followed. In the early 1980s two muscle relaxants of intermediate duration; atracurium and vecuronium>e> were introduced. The ideal neuromuscular blocking agent should have a rapid onset of action and non-depolarizing character.
Properties of an ideal muscle relaxant are: 91
1. Non-depolarizing mechanism of action (for being readily reversible by antidote).
2. Elimination independent of renal or hepatic functions.
3. No active or toxic metabolites.
4. Short duration of action and no cumulation.
5. Specification i.e. no side effects.
6. Residual neuromuscular block easily antagonized.
7. Rapid onset.